Asleep SBP is the most significant BP-derived risk factor for CVD events. Furthermore, treatment-induced decrease of asleep, but not awake SBP, a novel hypertension therapeutic target requiring periodic patient evaluation by ambulatory monitoring, is associated with significantly lower risk for CVD morbidity and mortality.
Ramon C Hermida, Juan J. Crespo, A Otero, Ana Moyá, Manuel Domínguez-Sardiña, María T. Ríos, M.C. Castiñeira, Pedro A. Callejas, Lorenzo Pousa, Elvira Sineiro, Sonia M. Gomara, José Luis Bernal Salgado, Carmen Durán, Juan José García Sánchez, Artemio Mojón, José R. Fernández, Diana E. Ayala
Discussion(0)
No comments yet. Be the first to comment.